Gri Bio Inc. has announced additional positive data from its Phase 2a clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The randomized, double-blind, placebo-controlled study enrolled 35 subjects and assessed safety, tolerability, pharmacokinetics, and pharmacodynamic activity over 12 weeks of once-daily oral administration. New immune profiling data from bronchoalveolar lavage fluid and peripheral blood mononuclear cells demonstrated inhibition of invariant natural killer T (iNKT) cell activity and a shift towards an anti-fibrotic immune profile. These results confirm the disease-modifying mechanism of GRI-0621 and reinforce earlier findings related to fibrosis resolution, lung repair, and improved lung function. The results have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9621983-en) on January 08, 2026, and is solely responsible for the information contained therein.